Alnylam to Webcast Presentation at Bank of America 2007 Health Care Conference
Posted on: Thursday, 24 May 2007, 09:00 CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Bank of America 2007 Health Care Conference on Wednesday, May 30, 2007, at 4:00 p.m. PT (7:00 p.m. ET) at the Four Seasons Hotel in Las Vegas, Nevada.
A live audio webcast of the presentation will be available on the "Investors" section of the company's website, www.alnylam.com. A replay of the presentation will be available on the Alnylam website within 48 hours after the event and will be archived for 14 days.
About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection. RSV infects nearly every child at least once by the age of two and accounts for more than 125,000 hospitalizations annually in the U.S. pediatric population. RSV infection also poses a great risk to the elderly and other adults with compromised immune systems. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. For more information, visit www.alnylam.com.
Source: Business Wire
Related Articles
- PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
- Pari's Electronic Nebulizer Delivers Alnylam's RNAi Therapeutic
- PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
- Alnylam Reports Phase I Clinical Safety Data for ALN-RSV01, an RNAi Therapeutic for the Treatment of RSV Infection; Results Reported at the 2006 Pediatric Academic Societies' Annual Meeting
- Alnylam To Collaborate With United States Army on RNAi Therapeutics for Biodefense Threats
- Alnylam Announces Product and Business Goals for 2006; Aims to Advance RNAi Therapeutic Clinical Pipeline, Execute on Strategic Alliances, and Build on Intellectual Property and Scientific Leadership Positions
- Alnylam Initiates Second Phase I Clinical Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection; Both U.S. And European Trials Now Underway
- Alnylam Initiates Phase I Clinical Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
- Alnylam Submits IND Application for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection; Represents First RNAi Therapeutic for Viral Infectious Diseases and Alnylam's Lead Clinical-Stage Program
- Alnylam Pharmaceuticals Initiates RNAi Therapeutic Development Program for Respiratory Syncytial Virus Infection
 |
 |
User Comments (0)
RSS Feeds